Cell and gene therapies require development of fit for purpose analytical tools to support bioprocess development, for biopharmaceutical characterization and lot release testing.
Webinar: Development of sensitive ADA assays using automated acid dissociation in Gyrolab Mixing CD 96
Measuring Anti-Drug-Antibody (ADA) levels is an important part of developing new biologics. The clinical implication of the presence of anti-drug-antibodies in treated patients may include allergic reactions, immune complex toxicity, autoimmune reactions and reduction of efficacy.
Products are for professional/laboratory use only. Gyros has developed a three-step bridging Gyrolab assay with a broad assay range (40 to 200,000ng/mL) for qualitative detection of total antibodies generated against the spike protein (RBD) of SARS-CoV-2 in human serum samples.
Impurity testing of biotherapeutics? Try the new Gyrolab CHO-HCP E3G Kit. Now available in a ready to use kit optimized for Gyrolab® Systems.